Nieder Carsten, Dalhaug Astrid, Haukland Ellinor
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.
Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Rep Pract Oncol Radiother. 2021 Sep 30;26(5):740-746. doi: 10.5603/RPOR.a2021.0096. eCollection 2021.
The prognostic assessment of patients referred for palliative radiotherapy can be conducted by site-specific scores. A quick assessment that would cover the whole spectrum could simplify the working day of clinicians who are not specialists for a particular disease site. This study evaluated a promising score, the LabBM (validated for brain metastases), in patients treated for other indications.
The LabBM score was calculated in 375 patients by assigning 1 point each for C-reactive protein and lactate dehydrogenase above the upper limit of normal, and 0.5 points each for hemoglobin, platelets and albumin below the lower limit of normal. Uni- and multivariate analyses were performed.
Median overall survival gradually decreased with increasing point sum (range 25.1-1.1 months). When grouped according to the original three-tiered model, excellent discrimination was found. Patients with 0-1 points had a median survival of 15.7 months. Those with 1.5-2 points had a median survival of 5.8 months. Finally, those with 2.5-3.5 points had a median survival of 3.2 months (all p-values ≤ 0.001).
The LabBM score, which is derived from inexpensive blood tests and easy to use, stratified patients into three very distinct prognostic groups and deserves further validation.
对于接受姑息性放疗的患者，可通过特定部位评分进行预后评估。一种能涵盖所有情况的快速评估方法可以简化非特定疾病部位专科临床医生的工作日。本研究评估了一种有前景的评分方法——LabBM（已在脑转移患者中验证），用于其他适应症患者的治疗。
对375例患者计算LabBM评分，C反应蛋白和乳酸脱氢酶高于正常上限各计1分，血红蛋白、血小板和白蛋白低于正常下限各计0.5分。进行单因素和多因素分析。
总生存中位数随总分增加而逐渐降低（范围25.1 - 1.1个月）。按照原有的三级模型分组时，发现有良好的区分度。0 - 1分的患者中位生存期为15.7个月。1.5 - 2分的患者中位生存期为5.8个月。最后，2.5 - 3.5分的患者中位生存期为3.2个月（所有p值≤0.001）。
LabBM评分源自廉价的血液检测且易于使用，可将患者分为三个非常不同的预后组，值得进一步验证。
